5 832

Cited 44 times in

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

DC Field Value Language
dc.contributor.author조상래-
dc.date.accessioned2015-04-24T17:17:38Z-
dc.date.available2015-04-24T17:17:38Z-
dc.date.issued2009-
dc.identifier.issn0924-8579-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105124-
dc.description.statementOfResponsibilityopen-
dc.format.extent92~93-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAcetamides/administration & dosage*-
dc.subject.MESHAcetamides/adverse effects-
dc.subject.MESHAcetamides/pharmacology-
dc.subject.MESHAcetamides/therapeutic use-
dc.subject.MESHAdult-
dc.subject.MESHAnti-Infective Agents/administration & dosage*-
dc.subject.MESHAnti-Infective Agents/adverse effects-
dc.subject.MESHAnti-Infective Agents/pharmacology-
dc.subject.MESHAnti-Infective Agents/therapeutic use-
dc.subject.MESHCulture Media-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHDrug Resistance, Multiple, Bacterial-
dc.subject.MESHExtensively Drug-Resistant Tuberculosis/drug therapy*-
dc.subject.MESHExtensively Drug-Resistant Tuberculosis/microbiology-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKorea-
dc.subject.MESHLinezolid-
dc.subject.MESHMale-
dc.subject.MESHMicrobial Sensitivity Tests-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMycobacterium tuberculosis/drug effects*-
dc.subject.MESHMycobacterium tuberculosis/isolation & purification-
dc.subject.MESHOxazolidinones/administration & dosage*-
dc.subject.MESHOxazolidinones/adverse effects-
dc.subject.MESHOxazolidinones/pharmacology-
dc.subject.MESHOxazolidinones/therapeutic use-
dc.subject.MESHSputum/microbiology-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTuberculosis, Multidrug-Resistant/drug therapy*-
dc.subject.MESHTuberculosis, Multidrug-Resistant/microbiology-
dc.subject.MESHYoung Adult-
dc.titleDaily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Microbiology (미생물학)-
dc.contributor.googleauthorHae-Seong Nam-
dc.contributor.googleauthorWon-Jung Koh-
dc.contributor.googleauthorO. Jung Kwon-
dc.contributor.googleauthorSang-Nae Cho-
dc.contributor.googleauthorTae Sun Shim-
dc.identifier.doi10.1016/j.ijantimicag.2008.06.014-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03824-
dc.relation.journalcodeJ01088-
dc.identifier.eissn1872-7913-
dc.identifier.pmid18789655-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0924857908002847-
dc.contributor.alternativeNameCho, Sang Nae-
dc.contributor.affiliatedAuthorCho, Sang Nae-
dc.citation.volume33-
dc.citation.number1-
dc.citation.startPage92-
dc.citation.endPage93-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, Vol.33(1) : 92-93, 2009-
dc.identifier.rimsid56767-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Microbiology (미생물학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.